NCT04820452View on ClinicalTrials.gov

A Study of IBI302 in Patients With nAMD

PHASE2CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

Low dose IBI302

Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection

BIOLOGICAL

High dose IBI302

High dose IBI302 intravitreal injection given as every other month after three loading monthly injection

DRUG

Aflibercept

Intraocular injection

Trial Locations (1)

215123

Innovent Biologics (Suzhou) Co,Ltd., Suzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY